01156nam a2200169   4500001000700000010001800007100004100025101000800066200013700074210008300211215001700294330056300311606001900874606002400893606000900917710006000926387625  a9789291683154  a20090420d2008       y0pory50      ba  aeng  aTowards a better understanding of drug-related public expenditure in EuropefEuropean Monitoring Centre for Drugs and Drug Addiction  aLuxembourgcOffice for Official Publications of the European Communitiesd2008  a28 p.d30 cm  aIntroductory note and acknowledgements. Introduction. Drug-related economic evaluation: key issues. Efficiency. Addressing efficiency through economic evaluation. Perspectives in economic evaluation. Cost studies. A particular perspective on costing: public expenditure. Drug-related public expenditure in Europe. Labelled expenditure. Non-labelled expenditure. Total drug-related expenditure in Europe. Conclusions and recommendations. Limitations of the study and future developments. The flip side of drug-related public expenditure. References. Glossary.  aESTUPEFACIENTE  aDESPESAS PÚBLICAS  aOEDT  aEUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION